September 2025 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, September 8) published advice on two medicines.

Blinatumomab (Blincyto®) was accepted for the treatment of adults with acute lymphoblastic leukaemia, a rare and aggressive form of leukaemia.

Rucaparib (Rubraca®) was accepted for use as maintenance treatment for adults with advanced ovarian cancer, following first-line chemotherapy.

SMC Chair Dr Scott Muir said: “The committee is pleased to be able to accept these new medicines for use by NHSScotland.

“Blinatumomab, used in the treatment of acute lymphoblastic leukaemia, reduces the risk of relapse and is expected to improve survival, giving patients extra time with their loved ones.

“Rucaparib will provide another treatment option for patients with advanced ovarian cancer.”